Skip to the story
All StoriesPoliticsConflict & SecurityBusiness & EconomyScience & TechHealthClimateMedia
All stories
Health16 outlets ran this4 min read

AI-designed drug rentosertib shows potential to reduce biological age markers

Secondary analysis of a phase 2a study suggests the drug may make patients appear biologically younger.

AI-assisted coverage comparison, editor-supervised · How this was made

Published
AI-designed drug rentosertib shows potential to reduce biological age markers

What this story says

  • Insilico Medicine's drug rentosertib, developed using generative AI, was analysed in a secondary study of 42 patients with idiopathic pulmonary fibrosis.
  • Six independent aging clocks indicated that patients treated with rentosertib appeared biologically younger than those receiving a placebo.
  • The most significant effect was observed in the 30mg twice-daily dosage group, where patients appeared 2.7 to 3.5 years younger on certain clocks at week four.
  • Study authors cautioned that the results cannot yet distinguish between slower aging and the effect of treating an inflammatory lung condition.

Who covered it

Left 13%(1)Centre 87%(7)Right 0%(0)

Percentages are shares of the 8 outlets carrying a published leaning rating. 8 of the 16 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .

Trust

50/100

Craft

65/100

Hype

45/100

16 sources · methodology

Insilico Medicine's drug rentosertib, designed with generative artificial intelligence, was the subject of a secondary analysis of a phase 2a study involving 42 patients with idiopathic pulmonary fibrosis. Proteomic data from these patients were analysed using six independent aging clocks. These analyses indicated that patients treated with rentosertib appeared biologically younger than those in the placebo group.

The largest observed effect was in the group receiving 30mg of rentosertib twice daily. At week four, these patients appeared 2.7 to 3.5 years younger on certain aging clocks. Alex Zhavoronkov, co-CEO of Insilico Medicine, stated that extending the healthy portion of life by three years could translate into significant productivity and savings.

The study authors noted a significant caveat: the results cannot yet definitively separate slower aging from the effects of treating the lung condition itself, as idiopathic pulmonary fibrosis is an inflammatory disease. They attempted to address this by showing that the 30mg twice-daily arm reversed age-associated protein patterns while the placebo group followed a normal aging trajectory, though this was considered suggestive rather than conclusive.

Disagreement on effect size

While the TNM report stated that the largest effect observed was between 2.7 and 3.5 years younger on certain clocks at week four, Insilico's own summary of the work described roughly three to four years, and up to six on certain clocks. The ZN.UA report stated that the average biological age of participants decreased by approximately six years after four weeks of the first dose.

What the coverage left out

None of the left or centre-rated reports mentioned the specific figure of 55,319 UK Biobank profiles used as a reference population in the proteomic analysis, as detailed in the TNM full report. Additionally, none of the centre-rated digests mentioned the seven patients who discontinued the trial due to liver toxicity, a detail present in the TNM full report.

Tags:#AIinMedicine#DrugDiscovery#AgingResearch#IdiopathicPulmonaryFibrosis#ClinicalTrials

Still developing. We have re-checked which outlets are covering this 4 times, most recently on 7 Sept 2026, 20:00, and will add the sides that appear.

How other outlets pictured it

Which photograph to run is each newsroom’s own choice. The leaning beside a name is that outlet’s published rating, not a claim that the pictures divide along it. Every picture is shown from the outlet’s own server and links to the article it ran in.

AI-designed drug rentosertib shows potential to reduce biological age markers
ZN.UA Зеркало неделиCentre

How each side covered it

Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.

Left

1 rated outlet

  • The single left-rated report, from TNM, led with the finding that AI-designed rentosertib lowered biological age markers in a 42-patient trial. It detailed the use of six independent aging clocks and quoted Alex Zhavoronkov, co-CEO of Insilico Medicine, stating that adding three years to everyone's life could significantly extend the healthy portion of life. The report also highlighted the study's limitations, noting that it could not yet separate slower aging from a treated lung, and that proteomic aging scores are not a regulatory endpoint for drug approval. It mentioned that rentosertib entered phase 3 trials in July.

Centre

7 rated outlets

  • The centre-rated reports focused on Insilico's AI-developed drug candidate showing anti-aging potential. Several digests, including MarketWatch, Wall Street Journal, News Medical, Bloomberg, and PR Newswire, highlighted that the drug rentosertib, designed with AI, demonstrated potential for biological age reversal. The ZN.UA report, which included a full article, stated that the drug reduced patients' biological age by approximately six years, quoting Insilico's CEO Alex Zhavoronkov on the potential to extend healthy life. The AI Journal and PR Newswire digests noted this was the first de-novo drug designed with generative AI for a de-novo target discovered using AI, and highlighted the consensus across six independently-developed proteomic aging clocks. Bloomberg and BizToc digests reported that the AI-discovered drug reversed aging markers in a study, according to the biotech company.

Right

0 rated outlets

No outlet rated right has run this story so far. We are still checking, and will say plainly if that does not change.

Questions about this coverage

How did the left and right cover AI-designed drug rentosertib shows potential to reduce biological age…?
Of the 8 outlets on this story carrying a published leaning rating, 13% are rated left, 87% are rated centre, 0% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 16. The sections above set out what each side emphasised, in its own terms.
Is AI-designed drug rentosertib shows potential to reduce biological age… left or right?
Too few of the outlets on this story carry a published leaning rating to say. 8 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
Is the coverage of AI-designed drug rentosertib shows potential to reduce biological age… biased?
AI-designed drug rentosertib shows potential to reduce biological age markers is one event reported by 16 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
Which outlets covered AI-designed drug rentosertib shows potential to reduce biological age…?
16 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
What is rentosertib and how was it developed?
Rentosertib is a drug developed by Insilico Medicine using generative artificial intelligence. It is being tested as a treatment for idiopathic pulmonary fibrosis, a lung disease. The AI was used to identify a target and then to design and optimise molecules.
What did the study on rentosertib find regarding aging?
A secondary analysis of a phase 2a study involving 42 patients indicated that those treated with rentosertib appeared biologically younger than those on placebo, according to six independent aging clocks. The largest effect showed patients appearing 2.7 to 3.5 years younger on certain clocks at week four.
What are the limitations of these findings?
Study authors cautioned that the results cannot yet definitively separate slower aging from the effects of treating the inflammatory lung condition, idiopathic pulmonary fibrosis. They also noted that proteomic aging scores are not a regulatory endpoint for drug approval.

Read it at the source

16 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.

Left

1

Centre

7

Right

0

No outlet in this group ran the story.

Not rated

8

How did this read?

About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.

More in Health

All Health →
US to phase out direct HIV funding for Namibia3 min readUS to phase out direct HIV funding for NamibiaRead storyAlcohol-linked cancer deaths in US more than doubled3 min readAlcohol-linked cancer deaths in US more than doubledRead storyPig kidney functions in patient for record 271 days2 min readPig kidney functions in patient for record 271 daysRead story

Elsewhere on the site

Rusija raskinula sporazum s NemačkomPolitics•3 min readCuba says US embargo caused $8bn in damages, denies talks with WashingtonBurnham and Trump agree to continue Ukraine ceasefire talksConflict & Security•5 min readBurnham and Trump agree to continue Ukraine ceasefire talksCopper prices hit a record high amid supply concernsBusiness & Economy•3 min readCopper Prices Hit Record High Amid Supply Concerns and Tariff FearsMayor Mamdani says he'll attend 9/11 ceremony despite growing criticismPolitics•3 min readMayor Mamdani to attend 9/11 ceremony amid criticism
Rentosertib Reduces Age Markers | MediaBias News